[Docetaxel in combination with epirubicin as the first-line chemotherapy for advanced and recurrent breast cancer: a multicenter phase II study].

Keisei Anan, Kazuo Tamura(Kindai University), Reiki Nishimura(Kumamoto City Hospital), Teruhiko Fujii(Translational Therapeutics (United States)), Maki Tanaka(Takara (Japan)), Hideki Taniguchi, Kazuo Chijiiwa, Shinji Ohno(Unknown), Tetsufumi Ohchi, Hiromichi Inoue, Masayuki Ohkido, Tatsuji Oikawa, Shinsuke Hara, Shoshu Mitsuyama(Kitakyushu Municipal Medical Center), Kazuo Shimada, Hiroshi Yano(Nagasaki University), Emi Ishikawa(Kyowa Chemical Industry (Japan)), Shigeru Imamura, Ichirou Arime

PubMed

May 1, 2012

Cited by 0

Related Papers

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2019|2.2k

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

|Annals of Oncology|2016|2.1k

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

|Annals of Oncology|2020|1.4k

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

|Annals of Oncology|2018|1.2k

Involvement of Protein Kinase C δ (PKCδ) in Phorbol Ester-induced Apoptosis in LNCaP Prostate Cancer Cells

|Journal of Biological Chemistry|2000|196